Adam J. Gadzinski, MD, MS, on the Design of a Study Assessing Impact of Telemedicine on Patient-Reported Outcomes

Video

The study sought to determine the impact of a rurally focused telemedicine program on patient outcomes.

In a study presented at the Society of Urologic Oncology 21st Annual Meeting, researchers sought to determine the impact of a rurally focused telemedicine program on patient outcomes in the urologic oncology outpatient clinic at the University of Washington Medical Center (UWMC).

Ultimately, it was revealed that telemedicine provides a medium for cancer care delivery that eliminates the significant travel burden associated with in-person clinic appointments.

In an interview with CancerNetwork®, Adam J. Gadzinski, MD, MS, urologic oncology fellow and an acting instructor of Urologic Oncology at the Urology Clinic at UWMC, explained the design for the study.

Transcription:
So, this was simply put a kind of prospective study where patients who had visits either via in person or via telemedicine were given a post-visit survey that asked questions both about patient satisfaction with the survey itself or with the visit itself, but also questions about travel expenses. Did they have to spend a night in a hotel? How many miles did they travel for? And looked at the differences between patients who had to come to our clinic in person versus those who had a telemedicine visit.

Recent Videos
Preliminary phase 2 trial data show durvalumab plus lenalidomide was superior to durvalumab alone in refractory/advanced cutaneous T-cell lymphoma.
Performance status, age, and comorbidities may impact benefit seen with immunotherapy vs chemotherapy in patients with breast cancer.
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.
Related Content